ArticleBlood2013
Effector T cells require fatty acid metabolism during murine graft-versus-host disease.
Article in Blood, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 137 citations in OpenAlex.
- Trial
- Trial
- CD80Cell communication and signaling : CCS · 2026Article
- Surgery-Induced Neutrophil Extracellular Traps Promote Tumor Metastasis by Reprogramming Cancer Cell Lipid Metabolism.Cancer research · 2025Article
- Chronic Graft-versus-host Disease, Part 1: How Preclinical Models Shape Our Understanding of Biology and Pave the Way for Future Therapeutic Interventions.Transplantation · 2025Review
- Metabolism of tumor infiltrating T cells.Frontiers in immunology · 2025Review
- Mitochondrial DAMPs as a critical driver in the development of acute graft versus host disease and emerging mitochondria targeted therapeutic strategies.Frontiers in immunology · 2025Review
- Article
- Fatty Acids Play a Critical Role in Mitochondrial Oxidative Phosphorylation in Effector T Cells in Graft-versus-Host Disease.ImmunoHorizons · 2024Article
- Analysis of the Immune Response by Standardized Whole-Blood Stimulation with Metabolism Modulation.Phenomics (Cham, Switzerland) · 2024Article
- Ubiquitination in the T Cell Metabolism-Based Immunotherapy in Diseases.Advances in experimental medicine and biology · 2024Review
- Fatty acid oxidation in immune function.Frontiers in immunology · 2024Review
- Transgelin 2 guards T cell lipid metabolic programming and anti-tumor function.Research square · 2023Article
- Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD.Blood advances · 2023Article
- Metabolic influences on T cell in psoriasis: a literature review.Frontiers in immunology · 2023Review
- From support to therapy: rethinking the role of nutrition in acute graft-versus-host disease.Frontiers in immunology · 2023Review
- Interplay between metabolic reprogramming and post-translational modifications: from glycolysis to lactylation.Frontiers in immunology · 2023Review
- The role of AMP-activated protein kinase in GVHD-causing T cells.Immunometabolism (Cobham, Surrey) · 2022Review
- Prevention of acute graft-vs.-host disease by targeting glycolysis and mTOR pathways in activated T cells.Experimental and therapeutic medicine · 2022Article
- Targeting Glycolysis in Alloreactive T Cells to Prevent Acute Graft-Frontiers in immunology · 2022Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Activated T cells require increased energy to proliferate and mediate effector functions, but the metabolic changes that occur in T cells following stimulation in vivo are poorly understood, particularly in the context of inflammation. We have previously shown that T cells activated during graft-versus-host disease (GVHD) primarily rely on oxidative phosphorylation to synthesize adenosine 5'-triphosphate. Here, we demonstrate that alloreactive effector T cells (Teff) use fatty acids (FAs) as a fuel source to support their in vivo activation. Alloreactive T cells increased FA transport, elevated levels of FA oxidation enzymes, up-regulated transcriptional coactivators to drive oxidative metabolism, and increased their rates of FA oxidation. Importantly, increases in FA transport and up-regulation of FA oxidation machinery occurred specifically in T cells during GVHD and were not seen in Teff following acute activation. Pharmacological blockade of FA oxidation decreased the survival of alloreactive T cells but did not influence the survival of T cells during normal immune reconstitution. These studies suggest that pathways controlling FA metabolism might serve as therapeutic targets to treat GVHD and other T-cell-mediated immune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.